bjkim97
☆    

Korea / Seoul,
2018-05-30 08:41
(1287 d 11:38 ago)

Posting: # 18828
Views: 1,874
 

 How to demonstrate the bioequivalence of sulodexide [Design Issues]

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ
Activity
 Admin contact
21,788 posts in 4,557 threads, 1,548 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Tuesday 19:20 CET (Europe/Vienna)

A big computer, a complex algorithm and a long time
does not equal science.    Robert Gentleman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5